Latest news
FDA approves Orzeyful, first drug to treat all symptoms of narcolepsy type 1 - Managed Healthcare ExecutiveManaged Healthcare Executive · Fri, 07 Aug 2026 20:06:51 GMTFDA Approves Oveporexton, First Orexin Receptor Agonist for Narcolepsy Type 1 - Patient Care OnlinePatient Care Online · Fri, 07 Aug 2026 06:16:23 GMTTakeda (TAK) Wins FDA Approval For First-In-Class Narcolepsy Drug Orzeyful With $2–3 Billion Peak Sales Target - londoninsider.co.uklondoninsider.co.uk · Fri, 07 Aug 2026 05:51:01 GMTFDA Approves Orzeyful, First Drug Targeting Underlying Cause of Narcolepsy - Drug TopicsDrug Topics · Thu, 06 Aug 2026 13:44:14 GMTFDA Okays First-in-Class Narcolepsy Drug Oveporexton - MedscapeMedscape · Thu, 06 Aug 2026 13:43:23 GMTTakeda’s narcolepsy nod opens orexin doors - BioSpaceBioSpace · Thu, 06 Aug 2026 13:17:40 GMTTakeda’s Orzeyful approved in US as first-in-class orexin treatment for narcolepsy Type 1 - European Pharmaceutical ReviewEuropean Pharmaceutical Review · Thu, 06 Aug 2026 10:35:42 GMTTakeda ushers in the orexin era with landmark FDA approval - AllSciAllSci · Thu, 06 Aug 2026 09:28:45 GMT